多西他赛联合吡柔比星在乳腺癌新辅助化疗中的应用  

Combination of docetaxel and pirarubicin in the neoadjuvant chemotherapy of breast cancer

作　　者：李青国[1] 周士福[1] 胡会华[1] 

机构地区：[1]苏州大学附属无锡第四人民医院肿瘤外科,江苏无锡214062

出　　处：《中国肿瘤临床与康复》2007年第1期33-34,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察多西他赛联合吡柔比星(THP)治疗局部晚期乳腺癌的近期疗效和毒性反应。方法48例局部晚期乳腺癌患者接受多西他赛75mg/m2,静滴,第1天;THP40mg/m2,第1天,静滴。21d为1个周期,完成3个周期。结果总有效率(CR+PR)为79.2%。主要不良反应有骨髓抑制和脱发(发生率分别为95.8%和97.9%)。结论多西他赛联合THP治疗局部晚期乳腺癌疗效显著,不良反应可耐受,是局部晚期乳腺癌新辅助化疗的有效方案。Objective To evaluate the efficacy and toxicity of docetaxel plus pirarubicin（THP） in the neoadjuvant chemotherapy of locally advanced breast cancer （LABC）. Methods Forty-eight patients with LABC were treated with docetaxel 75mg/m^2 ,dl ;THP 40 mg/m^2 ,d1. Each cycle was 3weeks,and 3 cycles comprised 1 course of treatment. Results The CR ＋ PR rate was 79.2%. The adverse reactions were myelosuppression and alopecia （ respectively 95.8% and 97.9% ）. Conclusion The combination of docetaxel and THP is well tolerated and is effective in neoadjuvant chemotherapy of LABC.

关 键 词：乳腺肿瘤/化学疗法 多西他赛 吡柔比星 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]